Skip to content

Effect of Diet Composition on Liver Fat and Glucose Metabolism

Effect of Diet Composition on Liver Fat and Glucose Metabolism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00930371
Acronym
DietLFAT
Enrollment
16
Registered
2009-06-30
Start date
2009-06-30
Completion date
2012-09-30
Last updated
2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver

Keywords

fatty liver, insulin resistance, diet, inflammation, oxidative stress

Brief summary

This study is designed to determine if the amount of fat and saturated fat in the diet contributes to the development of a condition called fatty liver disease in the absence of changes in weight.

Detailed description

A condition called non-alcoholic steatohepatitis is characterized by fat accumulation in the liver and associated inflammation. This condition is strongly associated with obesity, insulin resistance and type 2 diabetes. Diets high in saturated fat result in fatty liver, insulin resistance and liver injury in animal models. Dietary composition may contribute not only to hepatic fat accumulation and insulin resistance but may also promote inflammation leading to chronic liver disease in humans. This study will test the hypothesis that a diet high in fat and saturated fat contributes to liver fat accumulation, insulin resistance and inflammation by comparing the effects of a four-week, weight stable high fat/high saturated fat diet (55% calories from fat/25% saturated fat) with a four-week, weight stable low fat/low saturated fat diet (20% fat/8% saturated fat) in overweight and obese subjects.

Interventions

OTHERhigh fat/high saturated fat diet

4 weeks 55% fat/25% saturated fat isocaloric diet

OTHERlow fat/low saturated fat diet

4 weeks 20% fat/8% saturated fat isocaloric diet

Sponsors

VA Puget Sound Health Care System
CollaboratorFED
University of Washington
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-55 years old, men and women, otherwise in good general health, BMI \>27 kg/m2

Exclusion criteria

* Abnormal glucose tolerance, fasting glucose\>100 mg/dl or diabetes * History of liver condition or alanine aminotransferase (ALT) above the upper limit of the normal range * Use of medications that cause insulin resistance or fatty liver: niacin, glucocorticoids, estrogens, tamoxifen, amiodarone, accutane, sertraline, atypical antipsychotics, anti-HIV medications * Chronic use of anti-inflammatory medications (aspirin, ibuprofen, naprosyn, steroids, etc) * Average alcohol intake \>20 grams/day * Tobacco use * Creatinine \>1.5 mg/dl for men and \>1.4 mg/dl for women * Hematocrit \<33% * Pregnancy or lactation * Significant weight loss within the past 6 months (\>5% body weight) * Claustrophobia or any contraindications to being placed in the magnet for the MRS scan such as pacemakers, defibrillators, brain aneurysm clips, etc. * Other serious medical conditions or inflammatory conditions such as cancer, inflammatory arthritis, etc. * History of multiple food allergies or intolerances or severe food allergies * History of coronary artery disease, history of or treatment of hyperlipidemia, LDL \>200 mg/dl, fasting triglycerides \>300 mg/dl * Weight \>300 pounds

Design outcomes

Primary

MeasureTime frame
hepatic triglyceride content by MRS4 weeks

Secondary

MeasureTime frame
insulin sensitivity4 weeks
systemic and subcutaneous adipose tissue inflammation4 weeks
oxidative stress markers4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026